

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2025-08-06** | Period of Report: **2025-08-06**
SEC Accession No. [0001213900-25-072321](#)

[\(HTML Version on secdatabase.com\)](#)

FILER

OSR Holdings, Inc.

CIK: **1840425** | IRS No.: **845052822** | State of Incorporation: **DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **001-41390** | Film No.: **251187542**
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address
10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004

Business Address
10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004
425-635-7700

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2025

OSR HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	001-41390 (Commission File Number)	85-5052822 (IRS Employer Identification No.)
10900 NE 4th Street, Suite 2300, Bellevue, WA (Address of Principal Executive Offices)		98004 (Zip Code)

Registrant's telephone number, including area code (425) 635-7700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	OSRH	The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share	OSRHW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure

On August 6, 2025, OSR Holdings, Inc. (the “Company”) will host an investor presentation in connection with an Investor Event. A copy of the presentation materials that will be used during the event is attached hereto as Exhibit 99.1 and is incorporated herein by reference. These materials will also be made available on the Company’s investor relations website.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

EXHIBIT INDEX

Exhibit No. Description

99.1	Investor Presentation dated August 6, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 6, 2025

OSR HOLDINGS, INC.

By: /s/ Kuk Hyoun Hwang
Name: Kuk Hyoun Hwang
Title: Chief Executive Officer

2

OSR HOLDINGS

Innovation Headquarters | NASDAQ : OSRH



Investor Update | August 6, 2025

Forward Looking Statements



This material has been prepared by **OSR Holdings, Inc.** (the "Company") solely for the purpose of providing information during presentations intended for institutional and general investors. Redistribution, duplication, or transmission of this material to others is strictly prohibited.

Attendance at this presentation shall be deemed as agreement to comply with the above restrictions. Any violation of these restrictions may constitute a breach of applicable securities laws. All information regarding the Company's management performance and financial results contained herein has been prepared in accordance with corporate accounting standards.

The "forward-looking information" included in this material has not undergone individual verification procedures. This information pertains to future events rather than past ones and reflects the Company's expected business operations and financial performance. Expressions such as "expect," "forecast," or "outlook" are indicative of such forward-looking statements.

These forward-looking statements are subject to changes in future business environments and inherently involve uncertainties. As a result of these uncertainties, actual future performance may differ materially from what is stated or implied in the forward-looking information. Furthermore, all projections are based on conditions and assumptions as of the date of the presentation and may be subject to change without notice due to evolving market conditions and strategic revisions.

The Company, its affiliates, advisors, and representatives bear no liability whatsoever for any loss arising from the use of this material (including in cases of negligence or otherwise).

This document does **not** constitute an offer, solicitation, or recommendation to subscribe for or purchase any shares, and no part of this document should form the basis of, or be relied upon in connection with, any contract or investment decision.



Today's Agenda

- **Corporate overview and value drivers**
- **Subsidiary and R&D pipeline updates:**
 - Vaximm: versatile, cost-effective oral immunotherapies
 - Darnatein: innovative protein therapies
 - RMC: evolution to fourth party logistics
- **Woori IO acquisition: The opportunity in noninvasive CGM**
- **Equity Line of Credit (ELOC) financing strategy**
- **Live Q&A with management**

CGM, continuous glucose monitoring.

3

Executive Summary

Hub-and-Spoke Healthcare Holdco: OSRH currently holds 100% ownership in three Subcos across biotech and medical device sectors. Three global hub operations: Korea (Paju, Corporate HQ), Switzerland (Basel, Drug Development) and U.S. (Seattle, IR & Regulatory). Focused on advancing healthcare innovation globally to improve health and wellness outcomes.

Share Price Development Post-listing: During the final deSPAC process, from February 10th to 14th, a series of steep share price declines occurred from ~\$11 to below \$3 for no known fundamental reasons but only upon "short-term dynamics" while volumes were still thin as a SPAC. This share price drop did not represent any fundamental events or corporate or operational changes in any way.

Excessive Market Discount vs Peers: As of August 5, 2025, the company's market capitalization is approximately \$16 million. Compared to the median valuation of global peers at around \$500 million*, which suggests that the excessive and short sale-driven share price decline is likely to be corrected by underlying market fundamentals.

Portfolio Expansion Strategy: Recently signed Term Sheet to acquire 4th Subco in blood glucose monitoring (BGM/CGM) space with noninvasive technologies (i.e. no skin prick required). Represents ~\$10.9B annual market in 2024, estimated to grow at 16% CAGR to ~\$47.1B by 2034**. Further pipeline opportunities are under constant evaluation.

*Based on the S-4 Fairness Opinion filed by the Company; **Market Data from Global Market Insights.

4

Value Drivers

Hub-and-Spoke Biotech

- Hub provides centralized overarching expertise and resources
- Spokes focus on individual unique core competencies
- Flexibility to scale operations, promote collaboration, spread risk
- Reduced costs, enhanced efficiency and elevated probability of success

Vaximm: versatile, cost-effective oral immunotherapies

- Versatile proprietary platform directing cytotoxic T-cells against a wide range of epitopes with p.o. dosing
- Clinical stage VEGFR-2 inhibitor, VXM01, with preclinically proven anti-angiogenic activity, and encouraging Phase 1/2 safety profile in pancreatic cancer and GBM
- Development expansion into other oncology and non-oncology indications being investigated

Darnatein: innovative protein therapies


- Synthetic biology platform employing AI to generate "hybrid" versions of endogenous proteins with superior activity and excellent safety profile
- Lead asset DRT01 is engineered to function as BMP super-agonist for joint cartilage regeneration, targeting OA with huge unmet medical need and potential as a DMOAD
- Potential first-in-class approach addressing \$10B market annually with no current FDA-approved DMOAD

RMC: evolution to fourth party logistics

- Importer & distributor for neuro-intervention devices
- Active evolution to healthcare 4PL business to boost revenues an estimated tenfold in 3 years (with 10% OPM+)

4PL, fourth party logistics; AI, artificial intelligence; BMP, bone morphogenic protein; DMOAD, disease modifying osteoarthritis drug; GBM, glioblastoma; OA, osteoarthritis; OPM, operating margin; p.o., per oral; VEGFR, vascular endothelial growth factor receptor.

OSR Group



* To be increased to ~88% post-stock swap with Non-Participating Stockholder as set forth in the S-4 for Business Combination with BLAC. 4PL, fourth party logistics; DMOAD, disease modifying osteoarthritis drug; VEGFR, vascular endothelial growth factor receptor.

Holdco Management



Kuk Hyoun (Peter) Hwang, Chairman & Chief Executive Officer

- Founder & Managing Member, Bellevue Capital Management
- Korea Representative, Bellevue Asset Management AG
- Strategic Planning, Shinhan Securities



Constance Höfer, PhD, Chief Scientific Officer

- Executive Director & Global Program Head, Merck Group
- Global Program Head, Sandoz Biopharmaceuticals
- Chief Operating Officer, Priaxon AG



Sang Hoon (Harry) Kim, Head of Corporate Venture Capital

- Managing Director, APC Private Equity
- Head of Division, Meritz Asset Management
- Head of Overseas Investment, KDB Asset Management



Jun Whang, Chief Legal Officer

- General Counsel, Bellevue Capital Management
- Partner, Greenspoon Marder
- Partner, Jacob Medinger & Finnegan, LLP



Gihyoun (Chris) Bang, Chief Financial Officer


- VP, Newlake Alliance Management
- Team Leader, IPO Division, Shinhan Investment Corp



Josh Pan, PhD, MBA, Venture Partner

- Partner, Bellevue Capital Management
- Chief Business Officer, Landmark BioVentures
- VP Corporate Development & External Affairs, Athira Pharma
- Interim Chief Operating Officer, The W Fund

Corporate Milestones



Vaximm: Versatile, Cost-effective Oral Immunotherapies

- **Innovative:** T-cell mediated, selective elimination of diseased target cells via natural immune processes: oral route, high selectivity, low resistance potential, high tolerability
- **Robust, Safe & Versatile Delivery Technology:** Approved vector (Vivotif) plus variably encoded plasmid: “plug-and-play” capabilities, short technical, production and development timelines (anticipated concept to IND 18-24 months approx)
- **Wide Range of Possible Indications:** Oncology, infectious disease (e.g. HPV), ophthalmology, obesity
- **Low Treatment-Associated Costs:** Facile p.o. dosing at primary care centers or at home
- **Preclinical Proof-of-Concept:** VXM01 (anti-VEGFR-2) inhibits angiogenesis and tumor growth in vitro and in vivo
- **Clinical Experience to Phase 2:** VXM01 (anti-VEGFR-2) with encouraging results in pancreatic cancer and GBM, safety profile proven as amenable to combination therapies even in frail patient populations

HPV, human papillomavirus; IND, investigational new drug; p.o., per oral; VEGFR, vascular endothelial growth factor receptor.

9

Vaximm: Competitive Advantages, Potential to Disrupt

Factor	Conventional Biologic (mAb) Immunotherapy	Vaximm Immunotherapy
Production speed and versatility	Individual, dedicated cell line and MCB development for each mAb, including extensive selection/optimization	“Plug-and-play” Same plasmid/bacterial vector, production and scale-up for any epitope of choice
Treatment cost	>\$150k/year for innovative therapies	< \$50k estimated
Administration and treatment-associated costs	IV/SC at specialist care centers High (administration/supervision/travel)	Oral (primary care centers or at home) Low (homecare is possible)
Access	Focused on developed markets	Broad global accessibility

IV, intravenous; mAb, monoclonal antibody; MCB, master cell bank; SC, subcutaneous.

10

Vaximm: Potential Development Outlook for VXM01



Proof of Concept Studies

Future VXM01 clinical studies to demonstrate anti-VEGFR-2 mode of action and clinical activity

- Imaging, biomarkers, biopsies
- e.g. Neoadjuvant IO trials in GBM in treatment-naive patients: tumor imaging at diagnosis and post-treatment (pre-surgery), tumor material availability post-surgery
- Neoadjuvant trial operational advantages: patient characteristics, trial size, duration, and endpoints



Indication Expansion

VEGFR-2 overexpression-related diseases

- Oncology: e.g. breast, gastric cancer, angiosarcoma
- Ophthalmology: diabetic retinopathy, age-related macular degeneration
- Potentially implicated also in autoimmune disorders, pulmonary disease, and cerebrovascular disease*



CMC & Life Cycle Management

Further improvements of dosage form and production technology

- Potential extension of drug substance shelf-life
- Investigation of scope for solid drug substance(dried suspension)
- Development of capsule drug product (either liquid-filled or powder-capsule)
- Assessment of additional vector and plasmid technologies

*Shah et al. Archives of Pharmacol Research (2025).
GBM, glioblastoma; IO, immuno-oncology; VEGFR, vascular endothelial growth factor receptor.

Darnatein: Innovative Protein Therapies

Key Highlights

- Unique synthetic biology approach aided by design-augmented AI to develop novel protein chimeras with superior efficacy compared to original natural parent ligands
- Current focus on developing improved BMPs, which are important in bone and cartilage healing, but current BMP drugs require high doses, causing local and systemic side effects
- Darnatein DA-BMPs engineered for enhanced therapeutic potency, reducing required doses and minimizing the likelihood of adverse events

DRT-101: Potential disease-modifying treatment for osteoarthritis

- Chimeric Activin A/BMP7 protein with over 30x higher activity compared to natural BMP7
- Current preclinical data indicate DRT-101 potential as a first-in-class DMOAD
- Additional efficacy and safety studies to complete an IND-enabling package are underway
- Target 2026 IND submission (Korea) and subsequent submissions to other regulatory agencies to follow (EU, US)


DRT-102: Applications in bone fusion are already in clinical studies in Korea

- Excellent safety profile with efficacy data (75% bone fusion rate)
- Expected to be used as a reinforcing agent for spinal fusion and implant procedures for disc patients

BMP, bone morphogenic protein; DA, design augmented; IND, DMOAD, disease modifying osteoarthritis drug; IND, investigational new drug.

Darnatein: DRT-101 Market Potential as First Disease-modifying OA Therapy

Market Size Projection for DMOAD (\$billion)



Precedence Research: OA Therapeutics Market Size 2023 to 2034

- OA affects ~500 million people globally, its **prevalence continually rising** in aging populations worldwide
- OA is currently an **inexorably progressive disease**, standard of care drugs (NSAIDs, corticosteroids, hyaluronic acid etc.) don't slow or reverse joint degeneration once it has occurred
- **Joint replacement is currently the only "curative" treatment** but is highly invasive, expensive, requires extensive remobilization / rehabilitation therapy and the procedure poses additional risks, particularly in elderly patients
- DRT-101 has the potential to be a truly disease-modifying therapy to slow disease progression and delay or prevent surgery with potential to revolutionize OA care while tapping into a multi-billion-dollar opportunity

DMOAD, disease modifying osteoarthritis drug; NSAID, nonsteroidal anti-inflammatory drug; OA, osteoarthritis.


Darnatein: DRT-101 induces Cartilage Regeneration in vivo




MRI Imaging of in vivo OA model (rabbit) with and without intra-articular application of DRT-101



Control



DRT-101



Arrows highlight areas of absent (Control) and DRT-101 induced regenerated of hyaline cartilage

OA, osteoarthritis.

RMC: Evolving from Distribution to 4th Party Logistics

Key Highlights

Uniquely Positioned in the Fast-Growing yet Highly Fragmented Medical Device Market in Korea
 Korean medical device/diagnostics market value was \$14.9B (2024), projected to reach \$27.6B by 2033 at 8.4% CAGR
 RMC as part of OSR Holdings has rare opportunity to become a consolidator of the current market

Serving High Credit Clients

- Large hospital systems are the main customers of RMC's products
- Ultimately, it's the National Health Insurance Service (NHIS) who pays the bills for the hospitals
- RMC is in evolution right now to become one of the leading 4PL players in the Korean healthcare / hospital supply chain
- Default risk of NHIS is near zero while the hospital A/R cycle is 6 months

Growing Demands for Medical Device Sales Reps

- Market leaders assisting surgeons who need "live assistance" while providing continued training and support for medical staff across the country
- Plans to expand capabilities across Asia and globally underway

Products

Access Catheter	Intermediate Catheter	Coil for thrombus	Hemostasis Valve
			
Asahi Intecc	Microport	Microport	Hubiomed

Leadership



Chan Kyoo, Park
CEO

- Huteem Co., Ltd.
- Microvention, Inc
- Boston Scientific Korea
- Janssen Korea




Dong Jin, Shin
General Manager

- Fabmed Co., Ltd
- HUTEM CO., Ltd
- Meter Toledo Korea

*Source: verifiedmarketreports.com

RMC: Market Consolidation by RMC



Woori IO: Noninvasive CGM for Diabetes Management and Beyond



Woori IO GluCheck device uses proprietary NIRS-based (near-infrared spectroscopy) monitoring

- Signed term sheet in July with Woori IO (noninvasive CGM) to become wholly owned subsidiary of OSRK, pending due diligence.
- **Technology:** Uses proprietary near-infrared spectroscopy (NIRS) platform. Completed proof-of-concept, preparing for MFDS trial. Backed by Samsung C-Lab Outside (since Q1 2025).
- **Deal Structure:** Woori IO holders receive OSRK shares (convert to 12.96 OSRH @ \$10/share). If not met in 3 years, renegotiation required. No immediate dilution or cash payout.
- **Upside:** Early mover advantage, strategic tech, performance-based equity. Entry into global CGM market forecast to be worth \$47B by 2034*. Risks include regulatory milestones pending, due diligence pending, market volatility.
- **Integration Timeline:** 6-month exclusivity for due diligence. Definitive agreement targeted by October 2025 in good faith.

*Market Data from Global Market Insights. CGM, continuous glucose monitoring.

Woori IO: Noninvasive Glucose Monitoring Device



Key Highlights

South Korea-based Medtech startup pioneering non-invasive glucose monitoring technology

- Using near-infrared spectroscopy (NIRS) and a proprietary multi-LED sensor, Woori-IO's device measures blood glucose levels without drawing blood—offering a painless, convenient solution for diabetes management.


Completed exploratory clinical study at Korea University Guro Hospital

- Demonstrated **strong signal consistency** and reproducibility across repeated measurements
- Currently, Woori-IO is preparing for a **confirmatory (pivotal) clinical trial** to support regulatory approval as a medical device.


Selected for Samsung's C-Lab Outside program

- Continued year-over-year distribution demand and needs-based volume growth supports the vision to scale beyond initial Korean market into Asia and globally

Pipeline



Global Glucose Monitoring Market Outlook¹



*Grand View Research, "Blood Glucose Monitoring Devices Market Size Report, 2023-2030"

Financing: ELOC (Equity Line of Credit)

Addressing Concerns over Dilution

- Firstly, OSRH comes with “No Dilution At All” from the listing event
- The Founder still owns ~60.5% stake today – “We Need Dilution” as a public company
- ELOC allows us to control the timing and volume of equity issuance

With Disciplined Issuance, Aligned with Shareholder Value


- We retain full discretion over if, when, and how much to draw
- Strategic capital deployment aligned with milestone-driven growth
- Committed to minimizing dilution and maximizing value

19

Financing: Conceptual View of ELOC Drawdowns


Controlled Release :

Timely and strategic drawdowns



Frontloaded Release :


Compete for liquidity – “Execute immediately”



20

Financing: Theoretical "J-Curve Effect" of ELOC on Share Price

Illustrative Example of "J-Curve Effect" of Prudent ELOC Financing on Share Price



21

Vaximm: Valuation vs Peers




Comps Analysis

(Unit : USD m)	Market Cap ⁽¹⁾	Enterprise Value (EV)
Anixa Biosciences	98	83
Hookipa Pharma	11	-29
Oncolytics Biotech	96	85
Genelux	133	99
Immatix	788	188
Immutep	243	142
CEL SCI	49	57
Greenwich LifeSciences	148	146
Inovio	73	16
Northwest Biotherapeutics	371	438
Innate Pharma	195	139
Arcus Biosciences	970	33
Vaxcell Bio Therapeutics	153	132
Sillajen	283	214
Genexine	160	199
LigaChem Biosciences	3,313	2,982
ABL Bio	2,451	2,400
MedPacto	95	58
Mendus	50,410	43,824
Ultimovacs	27,325	14,371
Median Value of Comparables	178	140
Vaximm⁽²⁾	100	100
% Discount	44%	29%

DCF Analysis

(Unit : USD M)	Pipeline	Result
VXM 01		114
<i>rGBM</i>		22
<i>mCRC</i>		33
<i>Liver Cancer</i>		38
<i>Schwannoma NF2</i>		22
VXM Technology platform		70
Total		184

% Discount



1) As of August 1, 2025 from publicly available data
2) Stated equity value relates to OSR's acquisition of Vaximm, dated December 2022

22

Darnatein: Valuation vs Peers



Comps Analysis

(Unit : USD m)	Market Cap ⁽¹⁾	Enterprise Value (EV)
Medivir	23	17
Cytomics ⁽²⁾	104	104
Kolon TissueGene	2,170	2,156
MEDIPOST	251	205
Median Value of Comparables	177	154
Darnatein⁽³⁾	78	78
% Discount	56%	49%

DCF Analysis

(Unit : USD M)	Pipeline	Result
	DRT 101	104
Total		104

% Discount



- 1) As of August 1, 2025 from publicly available data
- 2) Based on August 2025 StartEngine Reg A+ pre-money valuation
- 3) Stated value relates to OSR's acquisition of Darnatein, dated March 2023

23

OSR Holdings: Summary

- Hub-and-Spoke healthcare group with global reach
- Proven management team across Biomedical and Capital Markets
- Market discount excessive vs peers
- Active Subco development with differentiated therapeutic platforms
- Strategic portfolio expansion to drive long-term value creation
- Disciplined capital management with prudent use of ELOC financing

24

Appendix: Financial Summary

Consolidated Statements of Financial Position

Consolidated Statements of Financial Position (USD)		
Account	Q1 2025	Q4 2024
ASSETS		
I. Current Assets	3,466,839	2,326,489
II. Non-Current Assets	171,083,358	172,913,090
Total Assets	174,550,197	175,239,579
LIABILITIES		
I. Current Liabilities	13,884,268	3,463,212
II. Non-Current Liabilities	28,383,452	28,568,152
Total Liabilities	42,267,720	32,031,364
STOCKHOLDERS' EQUITY		
Total Liabilities and Stockholders' Equity	174,550,197	175,239,579

Consolidated Statements of Comprehensive Income

Consolidated Statements of Comprehensive Income (USD)		
Account	Three Months Ended, Q1 2025	Three Months Ended, Q1 2024
Net Sales	761,272	910,225
Cost of Sales	592,586	670,424
Gross Profit	168,686	239,802
SG&A	3,086,512	3,542,330
Operating Loss	(2,917,826)	(3,302,528)
Other Income (Expense)	(8,474,988)	(52,834)
Loss before Income Taxes	(11,392,814)	(3,355,362)
Income Tax Benefit	-	(3.68)
Net Loss	(11,392,814)	(3,355,366)
Total Comprehensive Loss	(10,925,738)	(3,343,391)

Thank You



Email ir@osr-holdings.com
Website <https://osr-holdings.com>
Youtube <https://youtube.com/@osr-holdings>
Telegram https://t.me/osr_holdings_IR

Cover**Aug. 06, 2025**

Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 06, 2025
Entity File Number	001-41390
Entity Registrant Name	OSR HOLDINGS, INC.
Entity Central Index Key	0001840425
Entity Tax Identification Number	85-5052822
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	10900 NE 4th Street
Entity Address, Address Line Two	Suite 2300
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	425
Local Phone Number	635-7700
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Common stock, par value \$0.0001 per share	
Title of 12(b) Security	Common stock, par value \$0.0001 per share
Trading Symbol	OSRH
Security Exchange Name	NASDAQ
Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share	
Title of 12(b) Security	Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share
Trading Symbol	OSRHW
Security Exchange Name	NASDAQ

